Literature DB >> 11172766

Morphine tolerance after chronic intracerebroventricular injection in male and female mice.

B Kest1, E Hopkins.   

Abstract

We compared morphine analgesia ED(50) values of male and female mice prior to (Day 1) and after (Day 4) 3 days of intracerebroventricular morphine injections. Increases in ED(50) values from Day 1 to Day 4, indicating tolerance, were of similar magnitude in both sexes. The data suggest that spinal opioid analgesic mechanisms, acting alone or in synergy with supraspinal loci, may contribute to pharmacodynamic explanations of sex differences in systemic morphine tolerance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172766     DOI: 10.1016/s0006-8993(00)03301-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Region-specific mechanisms for testosterone-induced Fos in hamster brain.

Authors:  Anita Nagypál; Ruth I Wood
Journal:  Brain Res       Date:  2007-01-12       Impact factor: 3.252

2.  Gender rather than choice of intermediate duration opioids affects emergence after craniotomy for large intracranial tumors.

Authors:  Anupa Deogaonkar; Mimi Khin; Samuel Samuel; Zeyd Y Ebrahim; Edward J Mascha; Armin Schubert
Journal:  Ochsner J       Date:  2011

3.  Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-β Signaling, Not μ-Opioid Receptor Internalization.

Authors:  S Puig; K E Barker; S R Szott; P T Kann; J S Morris; H B Gutstein
Journal:  Mol Pharmacol       Date:  2020-07-28       Impact factor: 4.436

4.  A Review of Strain and Sex Differences in Response to Pain and Analgesia in Mice.

Authors:  Jennifer C Smith
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

5.  Repeated Morphine Administration Increases TRPV1 mRNA Expression and Autoradiographic Binding at Supraspinal Sites in the Pain Pathway.

Authors:  Thi-Lien Nguyen; Yun-Son Nam; Seok-Yong Lee; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2022-05-26       Impact factor: 4.231

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.